

GIL/GKP/2026-27

June 17, 2026

**BSE Limited**  
Floor 25, PJ Towers  
Dalal Street, Mumbai- 400 001  
INDIA  
Scrip Code: 532726

**National Stock Exchange of India Limited**  
"EXCHANGE PLAZA"  
Bandra - Kurla Complex, Bandra (East)  
Mumbai- 400 051. INDIA  
Symbol: GALLANTT

Dear Sir/Madam,

**SUB: NEWSPAPER PUBLICATION REGARDING SECOND 100 DAYS CAMPAIGN - "SAKSHAM NIVESHAK" – FOR KYC UPDATES AND SHAREHOLDER ENGAGEMENT TO PREVENT TRANSFER OF UNPAID / UNCLAIMED DIVIDENDS TO INVESTOR EDUCATION AND PROTECTION FUND ("IEPF")**

Please find attached herewith the newspaper cuttings for publication of Notice to Shareholders regarding "Saksham Niveshak" – Second 100 days campaign launched by the Investor Education and Protection Fund Authority (IEPFA), Ministry of Corporate Affairs, Government of India to facilitate investors in claiming their unpaid or unclaimed dividends, as well as in updating their KYC and related details. The said newspaper advertisement has been published in Business Standard (English – all edition) and Dainik Jagran (Hindi-Vernacular) on June 17, 2026.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

**For GALLANTT ISPAT LIMITED**

Nitesh Kumar  
(CS & COMPLIANCE OFFICER)  
M. No. F7496

Encl: As above

**GALLANTT ISPAT LIMITED**

CIN: L27109UP2005PLC195660

Registered Office & Gorakhpur Unit: Gorakhpur Industrial Development Authority (GIDA),  
Sahjanwa, Gorakhpur - 273209, Uttar Pradesh

Tele-fax: 0551 3515500, E-mail: csgml@gallantt.com, Website: www.gallantt.com

Gujarat Unit: Survey No. 175/1, Near Toll Gate, Samakhjali, Bhachau, Distt. Kutch - 370150, Gujarat

**GALLANT INVESTMENT PRIVATE LIMITED**  
**NOTICE TO SHAREHOLDERS REGARDING "SAKSHAM NIVESHAK" - SECOND 100 DAYS' CAMPAIGN**  
 Notice is hereby given to the shareholders of Gallant Invest Ltd ("The Company") in continuation of a regular campaign, the Investor Education and Protection Fund Authority (IEPA), Ministry of Corporate Affairs, Government of India, vide e-mail dated 11/06/2025 in the second 100 Days Campaign - "Saksham Niveshak", effective from 1st April, 2025 to 30th June, 2026 to facilitate investors in claiming their unpaid or unclaimed dividends, as well as to inform them of the various services available to them. As per the directives of the IEPA, the shareholders of the Company who have unclaimed dividends with the Company or whose KYC Details, (viz., PAN, Nomination details, postal address, mobile numbers, email, Bank account details and other details) have not been updated are requested to submit the below stated documents:  
 For shares held in physical form - Submit Investor Service Request Form (ISR-1, ISR-2, ISR-3) duly filled up and signed by the shareholder. The Aadhaar, latest address proof and original cancelled cheque leaf of bank account, through any of the following modes:  
 A. Hand carry to the Company or its RTA, M/s. Niche Technologies Private Limited at the following address:  
 Company Registrar and Share Transfer Agent (RTA)  
 The Company Secretary, Gallant Invest Limited, Concorde Industrial Development Corporation (CIDCO), Sahayra, Goregaur - 400032, Maharashtra, Goregaur - 400032, Uttar Pradesh Tel: 0551-3515500 Website: www.gallant.com  
 B. Scanned copies to the Company or your RTA atgallant.com or nichech@nichech.com respectively, provided they are sent through their registered e-mail address.  
 For shares in demat form-Shareholders are requested to contact their respective Depository Participants (DPs) to update their KYC details. All the above mentioned documents should be submitted to the Company at www.gallant.com and the RTA (https://nichech.com/india/india) respectively. In case of any queries or further assistance, shareholders may reach out to the Company or its RTA at the address mentioned above. The Company urges all shareholders to make their KYC details up-to-date and inform their rightful dividends and shares in order to avoid any transfer to IEPA.  
 Gallant Invest Limited Company Secretary  
 Date: June 16, 2026, Place: Goregaur

**EXIDE INDUSTRIES LIMITED**  
 EXIDE INDUSTRIES LIMITED, KOLKATA  
 CIN: L1402WB1947PLC014818  
 Registered Office: Exide House, 58 Chowringhee Road, Kolkata - 700 020  
 Phone: (033) 2302400/23022118 E-mail: exidestd@exidestd.com Website: www.exidestd.com  
**NOTICE OF THE 79th ANNUAL GENERAL MEETING OF THE COMPANY AND E-VOTING INFORMATION**  
 NOTICE is hereby given that the 79th Annual General Meeting (AGM) Meeting of Exide Industries Limited (NSDL) and e-Voting through Video Conferencing (VC) / Other Audio Visual Means (OAVM) will be held on **10th July 2026 at 10:30 AM (IST)** through Video Conferencing (VC) / Other Audio Visual Means (OAVM) facility to transact the business set out in the notice without the physical presence of Members at a common venue.  
 In accordance with the provisions of the Companies Act, 2013 and the Companies Act (MCA) and Securities and Exchange Board of India, the Company has decided to convene the AGM on the date mentioned above. The Company has appointed M/s. Registrar and Share Transfer Agent (RTA) or Depository Participant(s) as its RTA and is being sent to the Company providing the website, including the exact path which shareholders of the Company and the Integrated Report is available, to those shareholders who have not registered their e-mail address with the Company/Registrar and Share Transfer Agent (RTA) or Depository Participant(s). Further, a letter is being sent to the Company providing the website, including the exact path which shareholders of the Company and the Integrated Report is available, to those shareholders who have not registered their e-mail address with the Company/Registrar and Share Transfer Agent (RTA) or Depository Participant(s).  
 The Report is available on the website of the Company at [www.exidestd.com](http://www.exidestd.com) and on the website of the Stock Exchange viz. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com). The Notice of 79th AGM is also available on the website of National Securities Depository Limited (NSDL) at [www.evoting.nsdl.com](http://www.evoting.nsdl.com). Documents referred to in the Notice and Explanatory Statement will be available for inspection in electronic mode from date of circulation of this Notice up to the date of AGM. Members are requested to write to the Company at [exidestd@exidestd.com](mailto:exidestd@exidestd.com) for inspection of the said documents.  
**E-VOTING THROUGH ELECTRONIC MEANS**  
 Pursuant to the provisions of Section 108 of the Act read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), the Securities and Exchange Board of India issued by the Institute of Company Secretaries of India and the SEBI (E-Voting) Regulations, 2015 (as amended) and the Securities and Exchange Board of India issued by the Institute of Company Secretaries of India and the SEBI (E-Voting) Regulations, 2015 (as amended) and the Companies Act, 2013 and the Companies Act (MCA) Circulars, the Company is providing the facility of Remote e-Voting to its members in respect of the business to be transacted at the AGM and for this purpose, it has appointed NSDL to facilitate voting through electronic means.  
 The Remote e-Voting facility will be available during the following period:  
 Date and time of commencement of voting: 07th July 2026 (8:00 AM to 5:00 PM)  
 Date and time of conclusion of remote e-Voting: 09th July 2026 (8:00 AM to 5:00 PM)  
 Cut-off date for determining the eligibility for e-Voting: Friday, 03rd July 2026  
 Members may note that only persons whose names appear in the Register of Members, or in the list of beneficial owners furnished by National Securities Depository Limited (NSDL) and e-Voting through Video Conferencing (VC) / Other Audio Visual Means (OAVM) facility to transact the business set out in the Notice of 79th AGM shall be entitled to vote on the resolutions as set out in the Notice. The remote e-voting shall not be allowed beyond the said date and time. Once the vote on a resolution is cast by a member, he/she shall not be permitted to change it subsequently.  
 Members who have cast their vote through remote e-Voting may also attend the AGM but shall not be entitled to cast their vote again. Members attending the AGM who have not cast their votes through remote e-Voting will be able to vote through electronic voting facility through NSDL during the AGM.  
 Any person who acquires shares of the Company and becomes a member of the Company after the Notice is sent and holding shares as of the Cut-off date may obtain the login ID and password by sending a request to [exidestd@exidestd.com](mailto:exidestd@exidestd.com). Members who have not registered their e-mail address for remote e-Voting then he/she can use his/her existing User ID and password for casting the vote.  
 The procedure for e-Voting is available in the Notice of the 79th AGM. In case of any queries (queries) related to the e-Voting facility, members may contact the Assistant Manager (e-Voting user manual) members available in the downloads section of the e-Voting website of NSDL, <https://www.evoting.nsdl.com/>  
 Members who need assistance before or during the AGM, can contact NSDL on 022-4848700, or send an e-mail request to [helpdesk@nsdl.com](mailto:helpdesk@nsdl.com). Assistant Manager at [exidestd@exidestd.com](mailto:exidestd@exidestd.com) or Ms. Palvika Mishra, Senior Manager at [exidestd@exidestd.com](mailto:exidestd@exidestd.com).  
**Payment of Dividend, Record Date, Update of KYC and Nomination details**  
 The Company has fixed the Record Date as Friday, 03rd July 2026 to determine the members entitled to receive the proposed Final dividend of ₹ 2 per equity share of face value of ₹ 10 each (2026) for financial year ended 31st March 2026.  
 In accordance with Regulation 12 of SEBI Listing Regulations read with SEBI Master Circular No. H0361314/2026 - MFRS - PDD41269/26 dated 08th February 6, 2026, the Company has decided to provide the facility of remote electronic mode including to those who are holding securities in physical form. This payment shall be made only after the shareholders furnish their PAN, contact details (postal address, PAN and mobile number), bank account details, specimen signature ("KYC") and choice of Nomination.  
 In line with SEBI circulars, it is necessary for all holders of physical securities in listed entities to update their PAN, contact details (postal address with PIN and mobile number), bank account details and specimen signature ("KYC") and choice of Nomination with the Registrar and Share Transfer Agent (RTA) in case they have not updated the same. RTA will attend to all the requests of the shareholders only after the KYC details are updated in the records.  
 For the purpose of updation of KYC details, members are requested to send their filled mandatory forms available on the Company's website at [www.exidestd.com](http://www.exidestd.com), along with the necessary attachments to MUGF Intime India Pvt. Ltd. (Pursuant to merger with the Company Services (P) Ltd.) at their correspondence address: MUGF Intime India Pvt. Ltd., 20, Sir N. Mahipal Road, Kolkata - 700011 or e-mail to [cs@exidestd.com](mailto:cs@exidestd.com) or [investors\\_bolidesk@exidestd.com](mailto:investors_bolidesk@exidestd.com).  
 Members may note that pursuant to the Finance Act, 2020, dividend income is taxable in the hands of the Members effective 1st April 2020 and the Company is required to deduct tax at source (TDS) from dividend paid to Members at the prescribed rates. To enable compliance with TDS requirements, Members are requested to submit their Residential Address details to the Company in the prescribed Category as per Income Tax Act, 2023 with their Depository Participant if they hold shares in demat form, or in case shares are held in physical form, with the Company RTA, by sending documents through e-mail to [cs@exidestd.com](mailto:cs@exidestd.com) or [investors\\_bolidesk@exidestd.com](mailto:investors_bolidesk@exidestd.com) respectively latest by Monday, 1st July 2026.  
 The Company has appointed Mr. Anjan Kumar Iyer (CIN No. 5604 and CP No. 4557), Practising Company Secretary as the Scrutinizer, to scrutinize the voting process in a fair and transparent manner.  
 For Exide Industries Limited  
 Jitendra Kumar  
 Company Secretary  
 Place: Kolkata  
 Date: 16th June 2026

**KANPUR INVESTMENT PRIVATE LIMITED**  
 CIN: L25200UP1911PLC04344  
 Regd. Office: D-18-20, Park Industrial Area, Kanpur - 208 002, Tel: +91 (0512) 2891113 - 6, Email: [secretary@kanpur.com](mailto:secretary@kanpur.com), Web: [www.kanpur.com](http://www.kanpur.com)  
**Special Window for Transfer and Dematerialisation of Physical Securities**  
 Pursuant to SEBI Circular No. H0361314/2026-MFRS-PDD41269/26 dated January 09, 2026, the Company has opened a special window for the transfer and dematerialisation of physical securities that were sold or purchased prior to April 01, 2019. The window is open from 10th June 2026 to 30th June 2026. The window is available for those securities which were sold or purchased prior to April 01, 2019 but not processed or recorded or returned due to insufficiency of documents or for any other reason, subject to the condition that the securities are not listed on the stock exchange.  
 The securities so transferred shall be credited to the transferee in a dematerialized form and shall be subject to the provisions of the Securities and Exchange Act, 2013 and the SEBI (E-Voting) Regulations, 2015. The securities so transferred shall be subject to the provisions of the Securities and Exchange Act, 2013 and the SEBI (E-Voting) Regulations, 2015. The securities so transferred shall be subject to the provisions of the Securities and Exchange Act, 2013 and the SEBI (E-Voting) Regulations, 2015. The securities so transferred shall be subject to the provisions of the Securities and Exchange Act, 2013 and the SEBI (E-Voting) Regulations, 2015.  
 For further details, please refer to the SEBI Circular.  
 For Kanpur Plastpack Limited  
 Kanpur Plastpack Limited  
 Regd. Office: D-18-20, Park Industrial Area, Kanpur - 208 002, Tel: +91 (0512) 2891113 - 6, Email: [secretary@kanpur.com](mailto:secretary@kanpur.com)  
 Place: Kanpur  
 Date: 16.06.2026

**ENGINEERS INDIA LIMITED**  
 (A Govt. of India Undertaking)  
 A Navratna Company  
 4th Floor, Sector 17, Gurgaon, Haryana, India. Regd. Office: 110005, India  
 Website: [www.engineersindia.com](http://www.engineersindia.com), CIN: L74990IN19650004352  
 4th Floor, Sector 17, Gurgaon, Haryana, India  
**NOTICE**  
**Compulsory Transfer of Equity Shares to Investor Education and Protection Fund (IEPF) Authority**  
 This Notice is published pursuant to the provisions of Section 124(b) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the "Rules") notified by Ministry of Corporate Affairs, Government of India, which requires that all shares, in respect of which dividends have not been paid or claimed for seven consecutive years or more, shall be transferred to the IEPF Authority. Further, as per the IEPF Rules as amended, complete details of all unpaid or unclaimed dividends are regularly updated on the website of the Company, and with the Ministry of Corporate Affairs, Government of India.  
 The Company has sent individual communication to those shareholders whose shares are liable to be transferred to IEPF under the said Rules at their latest available address for claiming the unclaimed dividends due from the financial year 2015-16 (Final Dividend) onwards. The full details of such shareholders are also uploaded on the Company's website at [www.engineersindia.com](http://www.engineersindia.com). The Final Dividend 2015-16 which remained unclaimed/undeposited is also liable to transfer to IEPF. The details of those shareholders are also available on the Company's website.  
 In case, you do not receive your claim as per the above said communication by 19.10.2026 (IST 5:00 p.m.), all your relevant shares (whether held in physical or electronic form) will be transferred by the Company to the Demat Account of IEPF Authority on the next business day thereafter in accordance with the notifications/circulars issued by the Ministry of Corporate Affairs from time to time, without any further notice.  
 The shareholders who please note that no claim shall be against the Company in respect of the shares and dividends thereof credited to the Demat Account of IEPF Authority and subsequent to such transfer of shares to IEPF Authority, all future liabilities of the Company may accrue thereunder, including future dividends, shall be credited to IEPF Authority. You may note that, after the above referred transfer is made, refunds from the IEPF Authority can be claimed only by the shareholders who have received the Rules and a link in the report has been given on the website of the Company under Investor Section.  
 For further clarifications or assistance, you may write to us at:  
 Mr. Virender Sharma  
 Manager  
 Mr. S.K. Padi  
 Company Secretary  
 Engineers India Limited  
 E-1, Bhikaji Cama Place, New Delhi - 110066, India  
 Email: [company.secretary@eii.com](mailto:company.secretary@eii.com)  
 Tel: 011-26763451  
 For Engineers India Limited  
 Sd/-  
 Place: New Delhi  
 Date: 16.06.2026  
 Company Secretary

**PARRY AGRO INDUSTRIES LIMITED**  
 CIN: U01137NP1907PLC07980  
 Regd. Office: Parsi Street, 43, Malviya Nagar, New Delhi - 110017  
 E-mail: [secretary@pari.munugappa.com](mailto:secretary@pari.munugappa.com), Website: [www.pari001.com](http://www.pari001.com)  
 Tel: 011-42541224  
**16th ANNUAL GENERAL MEETING TO BE HELD**  
**OVER VIDEO CONFERENCE**  
 1. Shareholders may note that the 16th Annual General Meeting (AGM) of PARRY AGRO INDUSTRIES LIMITED will be held on Monday, 20th day of July, 2026 at 12 Noon IST by video Conferencing (VC) or other audio visual means (OAVM), in compliance with all the applicable provisions of the Companies Act, 2013 and the Securities and Exchange Board of India (SEBI) (E-Voting) Regulations, 2015 (as amended) and other applicable circulars issued by the Ministry of Corporate Affairs (MCA) and Government of India, to transact the business set out in the notice of the meeting.  
 2. In compliance with the above-mentioned circulars, the Annual General Meeting of the company will be held by video Conferencing (VC) or other audio visual means (OAVM). Hence, the members can attend only by way of VC facility. The electronic mode for participating in the meeting is subject to the notice for AGM.  
 3. In compliance with the circulars mentioned above, the members are hereby notified that the company will be sending electronic copies of the Notice of AGM and the annual report to the financial year ended 2025-26 to all the shareholders whose e-mail addresses are registered with the Company (Depository Participant(s)). The Notice of AGM and the annual report would be made available on the website of the company at [www.pari001.com](http://www.pari001.com).  
 4. Members who have not registered or wish to update their e-mail ID, postal address, telephone/mobile numbers, Permanent Account Number, bank account details are requested to register/update the same with their Depository Participant, if the shares are held in demat form and in case all members holding shares in physical form, all intimations are to be sent to KFN Technologies Limited at [steward.r@kfnitech.com](mailto:steward.r@kfnitech.com).  
 5. The Company is providing remote e-voting facility to all its members to cast their votes on all resolutions set out in the notice of the AGM. Additionally, the Company is providing the facility of voting through e-voting system during the AGM. Detailed procedure for remote e-voting / e-voting at the AGM is provided in the Notice of the AGM. The manner of voting remains the same for shareholders holding shares in dematerialized mode, physical mode and for shareholders who have not registered their e-mail address will be provided in the notice of the AGM. The instructions for joining the AGM will be provided in the notice of the AGM.  
 6. Shareholders may note that pursuant to provisions of section 91 of the Companies Act, 2013 read with rule 10 of the (Management and Administration) Rules, 2014, the Registrar of Members and the Share Transfer Books of the Company shall remain closed on Monday, 20th day of July, 2026 (both days inclusive), for the purpose of updation of entries of Members to Dividend for the Financial Year ended March 31, 2026.  
 7. Payment of dividend shall be made through electronic mode to the Members who have registered their Bank account details with the Company. Dividend which is not to be dispatched to the Registered Address of the Members who have not registered their bank account details.  
 8. Manner of registering mandate for receiving dividend:  
 Members are requested to register/update their bank account details:  
 • With their depository participants with whom they maintain their demat accounts, if shares are held in dematerialized mode.  
 • With KFN Technologies Limited (Registrar and Share Transfer Agent) by sending an email to [steward.r@kfnitech.com](mailto:steward.r@kfnitech.com). If shares are held in physical mode by submitting a scanned copy of the signed request letter which shall contain the Member's name, Folio Number, bank details (Bank Account Number, Bank Branch name and address, IFSC, MICR Details), Self-attested copy of PAN Card and Cancelled cheque.  
 9. The Dividend income is taxable in the hands of Members with effect from April 1, 2020 and the Company is required to deduct tax at source from the dividend paid to Members, as applicable. Accordingly, the Dividend for the FY 2025-26, is approved in accordance with the provisions of Income Tax Act, 2025.  
 TDS rates would vary depending on residential status of Members and the taxability of the dividend as per the provisions of the Income Tax Act, 2025.  
 A detailed note providing particulars of rate of tax to be deducted, documents to be submitted and the procedure to be followed by different categories of members is provided on the website of the Company under the Investor Section.  
 10. The IEPF AGM Notice will be sent to the shareholders in compliance with the applicable law or their registered address in due course.  
 On behalf of the Board of Directors  
 For PARRY AGRO INDUSTRIES LIMITED  
 M M Venkateshram  
 Chairman  
 Date: 16th June, 2026  
 Place: Chennai  
 DIN:50152819

**TATA MOTORS**  
**TATA MOTORS CHARTS SHIFT TO SOFTWARE-DEFINED VEHICLES**  
 TATA MOTORS Passenger Vehicle Ltd (TMLPV) is charting a software-defined vehicle (SDV) path, with future product launches set to ride on its proprietary t.tal architecture. The company is moving towards making software increasingly independent of underlying vehicle hardware, and building a new generation of digitally enabled vehicles.  
 In its 2025-26 (FY26) annual report, the company said T.tal would underpin upcoming product launches and form the foundation of its SDV strategy. TMLPV said it has established a "clear, phased road map" for the transition, and is working with technology partners to advance its architecture.  
 The road map envisages "a progressive shift towards greater compute and electronic architecture consolidation, with the long-term objective of abstracting system and software stack from underlying vehicle hardware", the company said.  
 TMLPV said its "progressive" on the SDV journey through the t.tal architecture, which will underpin upcoming launches. SDVs rely increasingly on software rather than "standalone" hardware. The architecture ranges from connectivity and infotainment to safety and driver assistance features, allowing new capabilities to be added through over-the-air updates, rather than through vehicle's lifecycle.  
 The company described SDVs as a "foundational shift" in how vehicles are designed, developed and experienced by customers, and said it would be "fundamental to the future of our product development strategy".  
 As part of this effort, work with Jaguar Land Rover's technology partner NVIDIA continued advanced engineering hubs to develop driver assistance systems, and artificial intelligence (AI) capabilities for next-generation electric vehicles (EVs) built on the NVIDIA DRIVE software-defined platform (SDV). According to the report, these technologies are expected to support active safety systems, autonomous driving and parking functions, driver assistance systems, driver and occupant monitoring, and advanced visualization of the vehicle environment. The company is also deploying NVIDIA Omniverse for digital twin design, and create digital twins of manufacturing facilities.  
 During FY26, Tata Motors expanded work on connectivity, over-the-air updates, and driver assistance systems. It built the software backbone positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker said. Indian biopharma is entering an "innovation power decade". It is better positioned to create value through specialty medicines and incremental innovation rather than attempting to replicate the new-molecule discovery model of global pharmaceutical companies.  
 Bernstein argues that Indian pharma is attempting to replicate the new-molecule discovery model of global pharmaceutical giants.  
 "Our proprietary model simulates 200x faster than the current model used in the Indian pharma sector with a positive outlook, the broker

